Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TPBG


Brief Information

Name:Trophoblast glycoprotein
Target Synonym:Trophoblast glycoprotein,5T4 oncotrophoblast glycoprotein,5T4,TPBG,5T4 oncofetal antigen,M6P1,5T4 oncofetal trophoblast glycoprotein,Wnt-Activated Inhibitory Factor 1,WAIF1,5T4AG,5T4-AG
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:11
Lastest Research Phase:Phase 2 Clinical

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
5T4 mAb - 01 Lead Solid Tumor Ovarian cancer,Lung cancer

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CHEK-ATP176-Cell-based assay

Expression analysis of human TPBG on HEK293/Human TPBG Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human TPBG Stable Cell Line or negative control cell using anti-human TPBG antibody followed by staining with PE anti-human IgG antibody.


Immobilized Cynomolgus / Rhesus macaque TPBG, His Tag (Cat. No. TPG-C52H3) at 1 μg/mL (100 μL/well) can bind Anti-TPBG Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).

TPBG MALS images

The purity of Rat TPBG Protein, His Tag (Cat. No. TPG-R52H6) is more than 90% and the molecular weight of this protein is around 42-57 kDa verified by SEC-MALS.

Synonym Name

TPBG,5T4,M6P1,5T4AG,WAIF1,5T4 oncofetal antigen,Trophoblast glycoprotein,5T4 oncofetal trophoblast glycoprotein


Trophoblast glycoprotein (TPBG), also known as 5T4, is the therapeutic target of several anticancer agents currently in clinical development, largely due to its high expression in tumors and low expression in normal adult tissues.This gene encodes a leucine-rich transmembrane glycoprotein that may be involved in cell adhesion. TPBG is expressed by all types of trophoblasts as early as 9 weeks of development.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Naptumomab estafenatox TTS-CD3; ABR-217620 Phase 2 Clinical Active Biotech Ab Carcinoma, Renal Cell; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung Details
ALG.APV-527 ALG-APV-527; ADC-1016; ATOR-1016; ALG.APV-527 Phase 2 Clinical Aptevo, Alligator Bioscience Ab Solid tumours; Neoplasms Details
OXB-301 OXB-301; SAR-109659 Phase 2 Clinical Oxford Biomedica Ovarian Neoplasms; Carcinoma, Renal Cell; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
SYD-1875 SYD-1875 Phase 1 Clinical Synthon Bv Solid tumours Details
ASN-004 ASN-004 Phase 1 Clinical Asana Biosciences Llc Solid tumours Details
ACR-246 ACR246; ACR-246 Phase 1 Clinical Hangzhou Adcoris Biopharmacy Co Ltd Solid tumours Details
FTL-008.16 FTL-008.16; FTL008.16 Phase 1 Clinical Sound(Chengdu)Biopharmacauticals Co Ltd Solid tumours Details
IBR-854 IBR854; IBR-854 Phase 1 Clinical Imbioray (Hangzhou) Biomedicine Co Ltd Solid tumours; Neoplasms Details
CBA-1535 CBA-1535 Phase 1 Clinical Chiome Bioscience Inc Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung Details
Anti-5T4 CAR-raNK Cell Therapy Phase 1 Clinical Imbioray (Hangzhou) Biomedicine Co Ltd Solid tumours Details
Prostate cancer vaccine(inactivated viral)(University of Oxford) Clinical University Of Oxford Prostatic Neoplasms Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message